Please login to the form below

Not currently logged in
Email:
Password:

NICE recommends Sutent

The National Institute for Health and Clinical Excellence has recommended Pfizer's Sutent as a possible first line drug treatment for people with advanced and/or metastatic renal cell carcinoma

The National Institute for Health and Clinical Excellence (NICE) has recommended Pfizer's Sutent (sunitinib) as a possible first line drug treatment for people with advanced and/or metastatic renal cell carcinoma. The new guidance applies to mobile patients who are suitable candidates for immunotherapy.  

Sutent was originally reviewed along with Roche's Avastin (bevacizumab), Bayer's Nexavar (sorafenib), and Wyeth's Torisel (temsirolimus) as part of a multiple technology appraisal. In August 2008, NICE advised against the use of all four drugs for this condition, but has since reassessed how it values medicines intended to extend life in terminal patients. In addition, Pfizer has also offered the initial six-week cycle of treatment with Sutent free of charge to the NHS. Guidance on the other three drugs is scheduled to be published in June.

Patient groups have welcomed the decision. Professor Robert Hawkins of Cancer Research UK said in a statement: "I am delighted that Sutent will be available. It will remove a great deal of anxiety and uncertainty for people diagnosed with renal cancer to know that modern, effective treatment is now available to them."

25th March 2009

From: Healthcare

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To transform lives through communication that changes behaviour and improves health outcomes....

Latest intelligence

JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
Virtual Speaker Program: A Customer Story
Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....